Pharmaceutical Technology

JUNE 10, 2025

MSD has received US Food and Drug Administration (FDA) approval for Enflonsia (clesrovimab-cfor) to prevent respiratory syncytial virus (RSV) lower respiratory tract disease in neonates and infants. Can pharma tariffs “Make America Manufacture Again”? Credit: MargJohnsonVA/Shutterstock.

FDA 52

FDA Research Laboratories Communication Hospitals 52

Pharmaceutical Technology

JULY 14, 2025

The US Food and Drug Administration (FDA) has accepted MSD’s doravirine/islatravir (DOR/ISL) new drug application (NDA) for review to treat adults with virologically suppressed human immunodeficiency virus (HIV)-1. Credit: ktsdesign/Shutterstock. In early July 2025, MSD agreed to purchase Verona Pharma in a transaction worth $10bn.

FDA 52

FDA Packaging Hospitals Research Laboratories 52

Pharmaceutical Technology

JUNE 16, 2025

MSD has received US Food and Drug Administration (FDA) approval for its anti-programmed death receptor-1 (PD-1) therapy, Keytruda (pembrolizumab), for adults with resectable locally advanced head and neck squamous cell carcinoma (HNSCC). Credit: Katherine Welles/Shutterstock. Don’t let policy changes catch you off guard.

FDA 52

FDA Research Laboratories Communication Hospitals 52